Morgan Stanley Maintains Overweight on SI-BONE, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri maintains an Overweight rating on SI-BONE (NASDAQ:SIBN) but lowers the price target from $21 to $19.
August 06, 2024 | 4:23 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley analyst Drew Ranieri maintains an Overweight rating on SI-BONE (NASDAQ:SIBN) but lowers the price target from $21 to $19.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100